Keymed Biosciences Inc., a biotechnology company, focuses on in-house discovery and development of biological therapies in the autoimmune and oncology therapeutic areas. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), chronic rhinosinusitis with nasal polyposis (CRSwNP), seasonal allergic rhinitis (SAR), prurigo nodularis, and respiratory related indications. The company is also developing CM512, which is in Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of CM512 in healthy subjects and patients with moderate-to-severe atopic dermatitis; CM313, a humanized monoclonal antibody that targets CD38 in Phase I/II clinical study; CM383, a humanized monoclonal antibody for the treatment of early Alzheimer's Disease; and CM326, a recombinant humanized monoclonal antibody targeting anti-thymic stromal lymphopoietin. In addition, it develops CMG901, a Claudin 18.2 antibody drug conjugate; CM518D1, an antibody drug conjugate; CM355, a CD20 x CD3 bispecific antibody, designed to bind both CD20 on tumor cells and CD3 on T-cells; CM336, a BCMA x CD3 bispecific antibody; CM350, a GPC3 x CD3 bispecific antibody for the treatment of solid tumors, especially for hepatocellular carcinoma; CM380, a GPRC5D x CD3 bispecific antibody; and CM369, an anti-C-C motif chemokine receptor 8 monoclonal antibody. The company has a license agreement with Belenos Biosciences, Inc.; Platina Medicines Ltd; Prolium Biosciences, Inc.; and Timberlyne Therapeutics, Inc. Keymed Biosciences Inc. was formerly known as 2Health Biosciences, Inc. The company was founded in 2016 and is headquartered in Chengdu, the People's Republic of China.